XNAS 29 Aug, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Rebecca Petersen | Director of Clinical Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 7,507 | 0 | - | - | Stock Option (right to buy) | |
| Rebecca Petersen | Director of Clinical Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.37 per share. | 18 Aug 2025 | 24,834 | 24,834 | - | 0.4 | 9,097 | Common Stock |
| Rebecca Petersen | Director of Clinical Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 17,327 | 3,694 | - | - | Stock Option (right to buy) | |
| Kang-Huai Johnny Wang | Director, See Remarks | 03 Jul 2025 | 11,111 | 0 | - | - | Series D Preferred Stock | ||
| Kang-Huai Johnny Wang | Director, See Remarks | 03 Jul 2025 | 446,896 | 721,732 | - | - | Common Stock | ||
| Kang-Huai Johnny Wang | Director, See Remarks | 03 Jul 2025 | 33,707 | 0 | - | - | Series C-1 Preferred Stock | ||
| Kang-Huai Johnny Wang | Director, See Remarks | 03 Jul 2025 | 35,947 | 0 | - | - | Series H Preferred Stock | ||
| Kang-Huai Johnny Wang | Director, See Remarks | 03 Jul 2025 | 1,407,407 | 0 | - | - | Series A Preferred Stock | ||
| Wen-Herng Henry King | Director | 03 Jul 2025 | 68,966 | 0 | - | - | Series H Preferred Stock | ||
| Wen-Herng Henry King | Director | 03 Jul 2025 | 20,710 | 20,710 | - | - | Common Stock | ||
| Hui Ying Kuo | Director | 03 Jul 2025 | 34,482 | 0 | - | - | Series H Preferred Stock | ||
| Hui Ying Kuo | Director | 03 Jul 2025 | 10,354 | 10,354 | - | - | Common Stock |